4C-I

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

4C-I, also known as iodo-Ariadne, 4C-DOI, or DOI-B, as well as 4-iodo-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-I and DOI, with 2C-I having no substitution at the α carbon, DOI having an α-methyl group, and 4C-I having an α-ethyl group.

In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin described testing 4C-I at doses of up to 4 mg orally, but observed no effects and did not assess higher doses. The drug is a potent agonist of the serotonin 5-HT 2A receptor. It shows similar efficacy as an agonist of this receptor as Ariadne, but has 12- to 16-fold higher activational potency in comparison. Like Ariadne, 4C-I produces an attenuated head-twitch response relative to the psychedelic drug DOPR, with a similar maximal response as Ariadne.

The chemical synthesis of 4C-I has been described. 4C-I first described in the scientific literature by Alexander Shulgin and colleagues in 1977. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.

4C-I, also known as iodo-Ariadne, 4C-DOI, or DOI-B, as well as 4-iodo-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-I and DOI, with 2C-I having no substitution at the α carbon, DOI having an α-methyl group, and 4C-I having an α-ethyl group.

In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin described testing 4C-I at doses of up to 4 mg orally, but observed no effects and did not assess higher doses. The drug is a potent agonist of the serotonin 5-HT 2A receptor. It shows similar efficacy as an agonist of this receptor as Ariadne, but has 12- to 16-fold higher activational potency in comparison. Like Ariadne, 4C-I produces an attenuated head-twitch response relative to the psychedelic drug DOPR, with a similar maximal response as Ariadne.

The chemical synthesis of 4C-I has been described. 4C-I first described in the scientific literature by Alexander Shulgin and colleagues in 1977. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371210500 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.